CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

TERN-101Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D065626 Non-alcoholic Fatty Liver Disease NIH 1.00
D005234 Fatty Liver NIH 1.00

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001397 Hepatic steatosis HPO 1.00

There is one clinical trial.

Clinical Trials

1 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.

NCT04328077 NASH - Nonalcoholic Steatohepatitis Drug: TERN-101 Other: Placebo
MeSH:Fatty Liver Non-alcoholic Fatty Liver Disease
HPO:Hepatic steatosis

Primary Outcomes

Measure: Subject incidence of adverse events for TERN-101 versus placebo

Time: 16 weeks

Secondary Outcomes

Measure: Percent change from baseline in ALT for TERN-101 versus placebo at 12 weeks

Time: 12 weeks

Description: Area under the curve

Measure: Plasma concentration of TERN-101 - AUC

Time: 12 weeks

Description: Maximum observed concentration

Measure: Plasma concentration of TERN-101 - Cmax

Time: 12 weeks

Description: Time to reach maximum measured plasma concentration

Measure: Plasma concentration of TERN-101 - Tmax

Time: 12 weeks

Description: Determination of half-life

Measure: Plasma concentration of TERN-101 - t1/2

Time: 12 weeks

Related HPO nodes (Using clinical trials)

HP:0001397: Hepatic steatosis
Genes 138
PLIN1 CAV1 BCS1L HNRNPA1 BSCL2 ETFB CPT2 PGM1 LDLR KCNAB2 TMEM199 CPT1A SLC25A13 SLC22A5 NGLY1 POLG MCCC1 LYRM4 DGUOK PPARG XRCC4 ALMS1 ATP7B PCK2 POLG LMNA HADHA COG6 NDUFAF1 APOE LIPE LDLRAP1 HNF4A TYMP PRDM16 MRPL44 MPV17 HADH HADH AKT2 APOB TFAM RRM2B SLC25A13 PCK1 TKFC DNAJC19 LMNA LMNA HNF1B ABCG5 LIPE LMNA MPV17 ACADM ACOX1 CYP19A1 VPS33A FARSB BSCL2 ALMS1 ETFDH CARS2 RERE CIDEC PHKG2 DDOST CIDEC PTRH2 LMNA DNAJC19 COX15 TARS2 ALDOB BCS1L POLD1 LMNB2 GPD1 SLC40A1 PLIN1 CYP7A1 ABCG8 ACADL LMNA CEP19 SLC40A1 CAV1 VCP ACADVL POLR3A CPT2 LARS1 MARS1 GABRD ADK AGPAT2 PNPLA2 TRAPPC11 LRPPRC PHKA2 SKI ACAD9 CBS ABHD5 NSMCE2 ATP6AP1 PCSK9 CAVIN1 BSCL2 FOS ABHD5 TRMU IARS1 HFE ETFA TRAPPC11 PPARG SAR1B ZMPSTE24 EARS2 FBP1 AGPAT2 HADHB ACAD9 HSD17B4 SLC25A13 MRPS7 PNPLA2 PMM2 NSMCE2 COA8 CLPB PPARG RMND1 CAVIN1 ACADM HNRNPA2B1 LIPA
Protein Mutations 4
C282Y E167K H63D I148M
SNP 10
rs1260326 rs2281135 rs2293152 rs2294918 rs2854116 rs2854117 rs58542926 rs641738 rs73049 rs738409